PDBSN peptide: mitochondrial support and oxidative stress reduction in human fat cells

[trojanpeptide]

PDBSN looks like a compound worth watching where mitochondrial health is concerned. The original publication can be found here.

Abstract:

Cellular energy production depends on mitochondria, and these organelles play a major role in obesity pathogenesis. Mature adipocytes were obtained by culturing human visceral and subcutaneous preadipocytes (HPA-v and HPA-s). Oil-red O staining and tissue triglyceride determination were used to measure intracellular triglyceride (TG) content. Fluorescent indicators served to assess mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) levels. Real-time quantitative PCR and Western blotting were employed to examine gene and protein expression tied to mitochondrial biogenesis. Electron microscopy revealed morphological changes. According to the results, PDBSN produced a significant rise in MMP alongside drops in TG and ROS. PGC1-α and MTFA transcription and protein levels rose, while markers of mitochondrial fusion and fission (MFN1, MFN2, NRF1, DRP1) increased. PDBSN also boosted maximum respiratory capacity and lowered ROS. Based on these findings, PDBSN appears to enhance mitochondrial function, which may offer insights for treating obesity and managing metabolic disease.

The literature gives an explicit definition of the PDBSN peptide as a 15‑amino‑acid sequence: GLSVADLAESIMKNL. This is taken straight from the paper that first identifies it as an anti‑adipogenic peptide, where it receives its name and the sequence is stated as “a novel peptide, PDBSN (GLSVADLAESIMKNL), that could significantly restrict adipocyte differentiation in vitro” (Shen et al., 2020). In the earlier mechanistic work, PDBSN is called a “novel peptide PDBSN” that inhibits adipogenesis through AMPK activation, yet that abstract does not spell out PDBSN; the sequence appears instead in the subsequent liposome‑encapsulation study (Shen et al., 2019).

Shen, D., Gao, J., Xia, J., Wang, X., Zhou, Y., Chen, L., Xu, L., & Guo, X. (2020). Liposome-encapsulated peptide PDBSN ameliorates high-fat-diet-induced obesity and improves metabolism homeostasis.. Biochemical and biophysical research communications. https://doi.org/10.1016/j.bbrc.2020.09.014

Shen, D., Li, Y., Wang, X., Wang, F., Huang, F., Cao, Y., You, L., Wen, J., Wang, Y., Cui, X., Ji, C., & Guo, X.-R. (2019). A novel peptide suppresses adipogenic differentiation through activation of the AMPK pathway.. Biochemical and biophysical research communications, 510 3, 395-402. https://doi.org/10.1016/j.bbrc.2019.01.112

Definitely seems like a solid research molecule.

 

[ftv10hb]

A lot of the technical details go right over my head, but I still enjoy taking a crack at it and seeing what I can pull from it lol. Is it accurate to say this basically repairs mitochondria through several different mechanisms, or could it also boost or enhance how well healthy mitochondria work? And how would you compare it to SS-31 when it comes to how it works and what it does?

 

[lessthanhalf]

Worth noting: the research behind this was done in cell cultures and mice, not people. It remains preliminary preclinical work, so using it in humans—whether in trials or on one's own—is still far off.

 

[trojanpeptide]

ftv10hb said:

A lot of the technical details go right over my head, but I still enjoy taking a crack at it and seeing what I can pull from it lol. Is it accurate to say this basically repairs mitochondria through several different mechanisms, or could it also boost or enhance how well healthy mitochondria work? And how would you compare it to SS-31 when it comes to how it works and what it does?

I'll have the AI break this down for you. Here's the rundown on PDBSN:

1. Mitochondrial Function Gets a Boost​#-1-enhancement-of-mitochondrial-functionPDBSN delivers major gains across key mitochondrial performance measures:

• Membrane Potential: It raises the mitochondrial membrane potential (MMP), a factor that matters greatly for generating energy.
  
• Energy Production: The peptide lifts ATP content and boosts the maximum respiratory capacity of the mitochondria.
  
• Oxidative Stress Reduction: Treatment with PDBSN produces a notable drop in reactive oxygen species (ROS), easing oxidative damage inside the cells.

2. New Mitochondria Are Encouraged to Form​#-2-promotion-of-mitochondrial-biogenesisAccording to the study, PDBSN drives the generation of fresh mitochondria:

• Protein Upregulation: Both transcription and protein levels of PGC1-α and MTFA (also called TFAM) rise substantially—these are key controllers of mitochondrial biogenesis.
  
• DNA Copy Number: In treated adipocytes, mitochondrial DNA (mtDNA) rose by roughly 30%.
  
• Morphological Improvements: Under electron microscopy, more mitochondria were seen, with less frequent swelling and vacuolation (indicators of damage) than in control groups. Fluorescence staining revealed greater mitochondrial density, especially around the perinuclear region and throughout the cytoplasm.

3. Mitochondrial Dynamics Are Modulated​#-3-regulation-of-mitochondrial-dynamicsPDBSN shifts the fusion-versus-fission balance, something necessary for a healthy mitochondrial network:

• Marker Elevation: Genes and proteins driving fusion (MFN1, MFN2) as well as fission (DRP1, NRF1) showed higher expression.
  
• Dynamic Equilibrium: Taken together, these results point to PDBSN supporting active mitochondrial turnover and remodeling.

4. Less Lipid Build-Up​#-4-reduction-of-lipid-accumulationThough this is mainly a metabolic outcome, the drop in stored lipids ties back to better mitochondrial function:

• Triglyceride Reduction: PDBSN treatment markedly lowered intracellular triglyceride (TG) levels and lipid deposition.
  
• Mechanism: Through enhanced mitochondrial respiration and ATP output, the peptide assists in managing energy expenditure, which stops the surplus energy accumulation that drives fat storage and mitochondrial dysfunction.

So my final answer would be 'supercharges'.

lessthanhalf said:

Worth noting: the research behind this was done in cell cultures and mice, not people. It remains preliminary preclinical work, so using it in humans—whether in trials or on one's own—is still far off.

Yes, I called it an interesting compound. But your remark doesn't quite fit this forum, because Khavinson peptides really have no human testing, and a few haven't even been tested in the tissue they're meant to act on—cartalax, for instance (research only in kidney cells, yet supposedly it fixes cartilage... bs). So I'm not sure about long way to consider for human consumption. MT-2 causes cancer and hypertension, and still plenty of people use it to lookmax.

 

[lessthanhalf]

When write-ups omit that their evidence comes only from cells or animals, readers can walk away thinking the science is far more settled than it actually is. Anyone who chooses to use peptides that have never been studied in humans is free to make that call, but that detail ought to come first. As it stands, many of these summaries and dosing schemes leave people believing human testing has been done and outcomes are established, which simply is not true.

On a GLP forum, these compounds are heavily researched, though a number of them have yet to wrap up phase 3 trials. A periodic nudge about the dangers of unstudied peptides will not sway everyone, yet it may offset the misplaced sense of safety created when write-ups detail effects drawn purely from cell or animal work without saying so. Once tens or hundreds of thousands of people start using peptides that never went through human clinical trials, unexpected and potentially severe side effects are bound to appear.

 

[DjJoshua]

trojanpeptide said:

PDBSN looks like a compound worth watching where mitochondrial health is concerned. The original publication can be found here.

Abstract:

Cellular energy production depends on mitochondria, and these organelles play a major role in obesity pathogenesis. Mature adipocytes were obtained by culturing human visceral and subcutaneous preadipocytes (HPA-v and HPA-s). Oil-red O staining and tissue triglyceride determination were used to measure intracellular triglyceride (TG) content. Fluorescent indicators served to assess mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) levels. Real-time quantitative PCR and Western blotting were employed to examine gene and protein expression tied to mitochondrial biogenesis. Electron microscopy revealed morphological changes. According to the results, PDBSN produced a significant rise in MMP alongside drops in TG and ROS. PGC1-α and MTFA transcription and protein levels rose, while markers of mitochondrial fusion and fission (MFN1, MFN2, NRF1, DRP1) increased. PDBSN also boosted maximum respiratory capacity and lowered ROS. Based on these findings, PDBSN appears to enhance mitochondrial function, which may offer insights for treating obesity and managing metabolic disease.

The literature gives an explicit definition of the PDBSN peptide as a 15‑amino‑acid sequence: GLSVADLAESIMKNL. This is taken straight from the paper that first identifies it as an anti‑adipogenic peptide, where it receives its name and the sequence is stated as “a novel peptide, PDBSN (GLSVADLAESIMKNL), that could significantly restrict adipocyte differentiation in vitro” (Shen et al., 2020). In the earlier mechanistic work, PDBSN is called a “novel peptide PDBSN” that inhibits adipogenesis through AMPK activation, yet that abstract does not spell out PDBSN; the sequence appears instead in the subsequent liposome‑encapsulation study (Shen et al., 2019).

Shen, D., Gao, J., Xia, J., Wang, X., Zhou, Y., Chen, L., Xu, L., & Guo, X. (2020). Liposome-encapsulated peptide PDBSN ameliorates high-fat-diet-induced obesity and improves metabolism homeostasis.. Biochemical and biophysical research communications. https://doi.org/10.1016/j.bbrc.2020.09.014

Shen, D., Li, Y., Wang, X., Wang, F., Huang, F., Cao, Y., You, L., Wen, J., Wang, Y., Cui, X., Ji, C., & Guo, X.-R. (2019). A novel peptide suppresses adipogenic differentiation through activation of the AMPK pathway.. Biochemical and biophysical research communications, 510 3, 395-402. https://doi.org/10.1016/j.bbrc.2019.01.112

Definitely seems like a solid research molecule.

Give it a run for a full cycle, then report back so ALL of us can hear how it turned out for you.....

 

[trojanpeptide]

I really don't think you'll find any supplier offering this peptide right now. My reason for bringing it up was simply to pass along some findings. Mitochondrial shortcomings are behind a lot of diseases and how they advance, so finding another peptide that might give us a tool against age-related illness seems like a win to me.

@lessthanhalf alright man. mouse studies have been done on it. It's not like this comes from a single experiment. Still, I'm wondering why you're calling this out for a peptide that does have research supporting it yet can't be bought, while you don't do the same for all the other peptides being sold right now that lack any evidence? No hard feelings either way, we're cool.

DjJoshua said:


You should do a cycle and let ALL of us know how it worked out for you.....

Click to expand...

if you cover the cost, I'm in

 

[lessthanhalf]

Every now and then I do post remarks along these lines regarding other peptides, though it feels a bit like pissing in the wind. My thinking was simply that the body of research behind these was thinner than usual, plus older and further from being ready for human trials. Take something like semax — thousands of people online have used it, which won't catch every possible adverse effect, but if serious problems were common, you'd likely see some signal in what people write about it.

AI's, when you don't prompt them, can produce descriptions of these peptides and their effects that sound quite authoritative, and they share the same flaw: they leave out the absence of human testing. So it really is easy to be misled about safety. My guess is that most of these peptides won't kill the people experimenting with them, but suppose a popular one raised cancer risk by a few percent — that could genuinely add up, and odds are there would never be any way to know it was the cause.

 

[trojanpeptide]

lessthanhalf said:

Every now and then I do post remarks along these lines regarding other peptides, though it feels a bit like pissing in the wind. My thinking was simply that the body of research behind these was thinner than usual, plus older and further from being ready for human trials. Take something like semax — thousands of people online have used it, which won't catch every possible adverse effect, but if serious problems were common, you'd likely see some signal in what people write about it.

AI's, when you don't prompt them, can produce descriptions of these peptides and their effects that sound quite authoritative, and they share the same flaw: they leave out the absence of human testing. So it really is easy to be misled about safety. My guess is that most of these peptides won't kill the people experimenting with them, but suppose a popular one raised cancer risk by a few percent — that could genuinely add up, and odds are there would never be any way to know it was the cause.

seriously? that is the Bandwagon Fallacy, plain and simple.

And AI? another wtf. That is a strawman. Nothing about this peptide came from AI for me, it came from reading publications.

So now sharing peptide information draws criticism just because the studies are in mice, while some of the peptides people actually use have NO studies at all, not even in mice, and that gets a pass since thousands of people are already doing it.

There's a document attached for you, no AI and no mice. Just plain fact.

 

[DjJoshua]

trojanpeptide said:


Guys, I seriously doubt any vendor is currently selling this peptide. I only dinged it to share some information. We are seeing many diseases and their progression is due to the inadequacies of the mitochondria, so another peptide which could possibly help us combat age-associated disease is a bonus in my books.

@lessthanhalf ok bro. it has been tested in mice. This isn't just from one study. But I am curious as to why you bother pointing that out with this peptide, which actually has data behind it but isn't commercially available, yet not for the plenitude of other peptides that have no evidence but that are being sold atm? Anyhow, no ill will, it's all good.

pay for it and i will

Click to expand...

how about setting up a gofundyou page?

 

[Airborne Daddy]

ftv10hb said:

A lot of the technical details go right over my head, but I still enjoy taking a crack at it and seeing what I can pull from it lol. Is it accurate to say this basically repairs mitochondria through several different mechanisms, or could it also boost or enhance how well healthy mitochondria work? And how would you compare it to SS-31 when it comes to how it works and what it does?

Or mots?

 

[trojanpeptide]

DjJoshua said:


maybe we can start a gofundyou page?

Click to expand...

honestly, in a living organism peptides such as this one likely wouldn't break down within just a minute. I'd put more effort into looking into or tweaking CGP42112A. Perhaps I'll put together a post on that one next time.

Airborne Daddy said:


Or mots?

Click to expand...

precisely, yet another possible contributor.

 

[lessthanhalf]

trojanpeptide said:

ftv10hb said:

A lot of the technical details go right over my head, but I still enjoy taking a crack at it and seeing what I can pull from it lol. Is it accurate to say this basically repairs mitochondria through several different mechanisms, or could it also boost or enhance how well healthy mitochondria work? And how would you compare it to SS-31 when it comes to how it works and what it does?

I'll have the AI break this down for you. Here's the rundown on PDBSN:

1. Mitochondrial Function Gets a Boost​#-1-enhancement-of-mitochondrial-functionPDBSN delivers major gains across key mitochondrial performance measures:

• Membrane Potential: It raises the mitochondrial membrane potential (MMP), a factor that matters greatly for generating energy.
  
• Energy Production: The peptide lifts ATP content and boosts the maximum respiratory capacity of the mitochondria.
  
• Oxidative Stress Reduction: Treatment with PDBSN produces a notable drop in reactive oxygen species (ROS), easing oxidative damage inside the cells.

2. New Mitochondria Are Encouraged to Form​#-2-promotion-of-mitochondrial-biogenesisAccording to the study, PDBSN drives the generation of fresh mitochondria:

• Protein Upregulation: Both transcription and protein levels of PGC1-α and MTFA (also called TFAM) rise substantially—these are key controllers of mitochondrial biogenesis.
  
• DNA Copy Number: In treated adipocytes, mitochondrial DNA (mtDNA) rose by roughly 30%.
  
• Morphological Improvements: Under electron microscopy, more mitochondria were seen, with less frequent swelling and vacuolation (indicators of damage) than in control groups. Fluorescence staining revealed greater mitochondrial density, especially around the perinuclear region and throughout the cytoplasm.

3. Mitochondrial Dynamics Are Modulated​#-3-regulation-of-mitochondrial-dynamicsPDBSN shifts the fusion-versus-fission balance, something necessary for a healthy mitochondrial network:

• Marker Elevation: Genes and proteins driving fusion (MFN1, MFN2) as well as fission (DRP1, NRF1) showed higher expression.
  
• Dynamic Equilibrium: Taken together, these results point to PDBSN supporting active mitochondrial turnover and remodeling.

4. Less Lipid Build-Up​#-4-reduction-of-lipid-accumulationThough this is mainly a metabolic outcome, the drop in stored lipids ties back to better mitochondrial function:

• Triglyceride Reduction: PDBSN treatment markedly lowered intracellular triglyceride (TG) levels and lipid deposition.
  
• Mechanism: Through enhanced mitochondrial respiration and ATP output, the peptide assists in managing energy expenditure, which stops the surplus energy accumulation that drives fat storage and mitochondrial dysfunction.

So my final answer would be 'supercharges'.

lessthanhalf said:

Worth noting: the research behind this was done in cell cultures and mice, not people. It remains preliminary preclinical work, so using it in humans—whether in trials or on one's own—is still far off.

Yes, I called it an interesting compound. But your remark doesn't quite fit this forum, because Khavinson peptides really have no human testing, and a few haven't even been tested in the tissue they're meant to act on—cartalax, for instance (research only in kidney cells, yet supposedly it fixes cartilage... bs). So I'm not sure about long way to consider for human consumption. MT-2 causes cancer and hypertension, and still plenty of people use it to lookmax.

You can tell right away that this post was produced and laid out by AI, and that is exactly why I brought up AI in my comment. When people recall things and type on forums, their writing simply does not look like that. AI tools can be genuinely helpful and can carry solid pharmacology knowledge, yet I will not put my trust in what an AI produces when nobody has prompted or checked it.

As for semax, I would not call its safety established. Still, thousands of posts about it exist online, and the scarcity of reported side effects is itself real data. It is far from fully dependable, but a small unreliable scrap of data beats having none at all. Confirmation bias will always color how side effects get reported on forums, yet plenty of accounts describe odd or one-of-a-kind reactions, which implies that users do report effects that expectation alone would not have produced. Not long ago I came across a paper where AI analyzed GLP side effects drawn from reddit posts, and it turned up side effects that had not been documented before.

All those enthusiastic claims that KLOW or GLOW cures this or that ailment, I do not treat as trustworthy. Side effects reported for it, on the other hand, I would take seriously.

Side effects discussed on this forum for GLP drugs are useful in the same way, and they have included several reports of effects absent from the reta studies, among them panic attacks, hiccoughs that drag on, and arrythmias. Beyond that, the side effects people report here for GLP drugs line up closely with the research.

Research done on cells or in mice bothers me not at all, and it interests me, since that is where the bulk of research happens. My only point is that it is better when the source of that research is stated plainly, given that most people never read the science papers behind the information, and because of that they frequently do form mistaken impressions. Peptide sellers and promoters, I would argue, do this on purpose and deliberately, to make their peptides easier to sell and to create false impressions of safety or efficacy. Sadly, given how people's minds operate, simply repeating a claim often enough, accurate or not, is sufficient to make people accept it as true.

 

[trojanpeptide]

@lessthanhalf , I had AI put together a summary for me. Honestly, I think it nailed it ! Also, PDBSN actually has studies done on human adipocytes — that puts it ahead of plenty of other peptides. No hard feelings, man. I just wish we could have talked about the peptide itself rather than... I don't know, safety concerns or whatever. There are a few peptides I find fascinating, and some I'd even want to tweak, but yeah, I don't have the kind of money that game demands.

anyway, I'm gonna sit back on the rhetoric fight; rigorous science = a good conversation.